Litigation Details for Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)
Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-10-11 |
| Court | District Court, D. Delaware | Date Terminated | 2018-09-20 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Defendant | Referred To | |
| Parties | 3M COMPANY | ||
| Patents | 9,724,310; 9,730,900; 9,833,419 | ||
| Attorneys | Dominick T. Gattuso | ||
| Firms | Polsinelli PC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-10-11 | External link to document | |||
| 2017-10-11 | 1 | infringement of U.S. Patent Nos. 9,730,900 (“the ’900 patent”) and 9,724,310 (“the ’310 patent”) (collectively…infringing the ’900 patent. COUNT II – INFRINGEMENT OF U.S. PATENT NO. 9,724,310 66. …collectively, “patents-in-suit”) arising under the United States Patent Laws, Title 35, United States Code § … PATENTS-IN-SUIT 35. The ’900 patent, entitled “Transdermal Estrogen…concerning the ’900 patent to the FDA in connection with NDA No. 203752, identifying it as a patent “with respect | External link to document | |
| 2017-10-11 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,730,900 B2; 9, 724,310 B2. … 20 September 2018 1:17-cv-01429 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
